No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
TP53 mutation	Chronic Myelomonocytic Leukemia	TP53 mutation	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B
TP53 mutation	Chronic Myelomonocytic Leukemia	TP53 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C1 - Off-label venetoclax Sensitive : C1	venetoclax Sensitive: C1 - Off-label venetoclax Sensitive : C1
RUNX1 mutation	Chronic Myelomonocytic Leukemia	RUNX1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
NRAS mutation	Chronic Myelomonocytic Leukemia	NRAS mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
CBL mutation	Chronic Myelomonocytic Leukemia	CBL mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
KRAS mutation	Chronic Myelomonocytic Leukemia	KRAS mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
IDH2 mutation	Chronic Myelomonocytic Leukemia	IDH2 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
IDH1 mutation	Chronic Myelomonocytic Leukemia	IDH1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
NPM1 mutation	Chronic Myelomonocytic Leukemia	NPM1 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
TET2 mutation	Chronic Myelomonocytic Leukemia	TET2 mutation	Chronic Myelomonocytic Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
NRAS G12D	Chronic Myelomonocytic Leukemia	NRAS G12D	Chronic Myelomonocytic Leukemia	trametinib Resistant: C4 – Case Studies trametinib Resistant : C4	trametinib Resistant: C4 – Case Studies trametinib Resistant : C4
RANBP2-ALK fusion	Chronic Myelomonocytic Leukemia	RANBP2-ALK fusion	Chronic Myelomonocytic Leukemia	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4	cytarabine + daunorubicin Sensitive: C4 – Case Studies cytarabine + daunorubicin Sensitive : C4
CBL C384Y	Chronic Myelomonocytic Leukemia	CBL C384Y	Chronic Myelomonocytic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D
KDM6B overexpression + TET2 deletion	Chronic Myelomonocytic Leukemia	KDM6B overexpression + TET2 deletion	Chronic Myelomonocytic Leukemia	GSKJ4 Sensitive: D – Preclinical GSKJ4 Sensitive : D	GSKJ4 Sensitive: D – Preclinical GSKJ4 Sensitive : D
KRAS G12D	Chronic Myelomonocytic Leukemia	KRAS G12D	Chronic Myelomonocytic Leukemia	trametinib Resistant: D – Preclinical trametinib Resistant : D	trametinib Resistant: D – Preclinical trametinib Resistant : D
NRAS G12D	Chronic Myelomonocytic Leukemia	NRAS G12D	Chronic Myelomonocytic Leukemia	selumetinib Resistant: D – Preclinical selumetinib Resistant : D	selumetinib Resistant: D – Preclinical selumetinib Resistant : D
KRAS G12D	Chronic Myelomonocytic Leukemia	KRAS G12D	Chronic Myelomonocytic Leukemia	selumetinib Resistant: D – Preclinical selumetinib Resistant : D	selumetinib Resistant: D – Preclinical selumetinib Resistant : D
CBL mutation	Chronic Myelomonocytic Leukemia	CBL mutation	Chronic Myelomonocytic Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D

Chronic Myelomonocytic Leukemia

Associations(20)

Associations
(20)